Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCC )

0.6325 -0.0075 (-1.17%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,907
Open 0.6700
Bid (Size) 0.6321 (6)
Ask (Size) 0.6697 (9)
Prev. Close 0.6400
Today's Range 0.6302 - 0.6700
52wk Range 0.5000 - 2.410
Shares Outstanding 12,539,189
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Cyclacel Pharmaceuticals Q1 Earnings
 
Via Benzinga
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire

Performance

YTD
-8.68%
-8.68%
1 Month
+7.19%
+7.19%
3 Month
-18.07%
-18.07%
6 Month
-23.56%
-23.56%
1 Year
-47.29%
-47.29%

More News

Read More
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know
Via Benzinga
A Preview Of Cyclacel Pharmaceuticals's Earnings
Via Benzinga
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Earnings Outlook For Cyclacel Pharmaceuticals
Via Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
From Cyclacel
Via GlobeNewswire
Cyclacel Hosting Research & Development Day
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
From Cyclacel
Via GlobeNewswire
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Via Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.